Pneumatic displacement of submacular haemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

Eye (Lond). 2024 Dec;38(17):3374-3381. doi: 10.1038/s41433-024-03318-4. Epub 2024 Sep 19.

Abstract

Background: To compare the visual and anatomical outcomes of pneumatic displacement (PD) combined with anti-vascular endothelial growth factor (VEGF) therapy versus anti-VEGF monotherapy in treatment-naive eyes with submacular haemorrhage (SMH) secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Methods: In a retrospective comparative interventional study of 57 eyes, the changes in logMAR visual acuity (VA), and SMH height and area at baseline at months 1, 3 and 12 were compared between the PD and non-PD groups.

Results: There was no significant difference in mean VA in the PD versus non-PD group at month 12 (1.1 versus 0.7, p = 0.09). At baseline, the PD group, compared to the non-PD group, had significantly larger SMH area (35.9 versus 26.9 mm2, p = 0.04) and SMH height at the fovea (733.7 versus 503.6 µm, p < 0.01). The greatest reduction in SMH height and area occurred between baseline and month 1 in the PD group, which was faster than between month 1 and month 3 in the non-PD group, with similar findings in the matched pair analysis matched for SMH height and area. In the multivariable analysis, only baseline VA was associated with VA outcomes (month 1: β = -0.46, 95% [confidence interval] CI = -0.78 to -0.14, p = 0.006; month 3: β = -0.52, 95% CI = -0.86 to -0.18, p = 0.004; and month 12: β = -0.78, 95% CI = -1.16 to -0.39, p < 0.001).

Conclusions: The visual outcome of SMH at month 12 in nAMD and PCV is poor regardless of whether PD is performed in addition to anti-VEGF therapy, although a more rapid resolution of SMH can be expected.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors* / therapeutic use
  • Bevacizumab / therapeutic use
  • Choroid / blood supply
  • Choroid Diseases / complications
  • Choroid Diseases / diagnosis
  • Choroid Diseases / physiopathology
  • Choroidal Neovascularization / drug therapy
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / physiopathology
  • Choroidal Neovascularization / therapy
  • Combined Modality Therapy
  • Endotamponade
  • Female
  • Fluorescein Angiography
  • Fluorocarbons / administration & dosage
  • Humans
  • Intravitreal Injections*
  • Male
  • Polypoidal Choroidal Vasculopathy
  • Polyps / complications
  • Polyps / diagnosis
  • Polyps / physiopathology
  • Ranibizumab* / administration & dosage
  • Ranibizumab* / therapeutic use
  • Retinal Hemorrhage* / diagnosis
  • Retinal Hemorrhage* / etiology
  • Retinal Hemorrhage* / physiopathology
  • Retinal Hemorrhage* / therapy
  • Retrospective Studies
  • Tomography, Optical Coherence*
  • Vascular Endothelial Growth Factor A* / antagonists & inhibitors
  • Visual Acuity* / physiology
  • Wet Macular Degeneration* / complications
  • Wet Macular Degeneration* / diagnosis
  • Wet Macular Degeneration* / drug therapy
  • Wet Macular Degeneration* / physiopathology

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A
  • Ranibizumab
  • VEGFA protein, human
  • Bevacizumab
  • perflutren
  • Fluorocarbons